Literature DB >> 19232880

Prognostic factors in localized extremity osteosarcoma: a systematic review.

J A M Bramer1, J H van Linge, R J Grimer, R J P M Scholten.   

Abstract

AIM: Finding reliable prognostic factors for osteosarcoma remains problematic. A systematic review [Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. Journal of Clinical Oncology 1994; 12(2): 423-431.] showed chemotherapy response as only independent factor. We tried to identify evidence-based prognostic factors in the literature since 1992 and to establish pooled relative risks of factors.
METHODS: MEDLINE and Embase search (1992-August 2006). Two reviewers independently selected papers addressing prognostic factors in localized extremity osteosarcoma, which were studied for methodological quality, and valuable new factors. An attempt was made to pool results.
RESULTS: Of 1777 "hits", 93 papers were studied in depth. Several "new" prognostic factors were found. Only 7 papers were of sufficient quality to analyze. Chemotherapy response, tumor size and site, alkaline phosphatase level and p-glycoprotein expression seemed to be independent factors. Some new factors looked promising.
CONCLUSIONS: Although the literature is abundant, it is disappointing that only few papers are of sufficient quality to allow hard conclusions. Because of heterogeneity of the studies pooling results is hardly possible. There is a need for standardization of studies and reports.

Entities:  

Mesh:

Year:  2009        PMID: 19232880     DOI: 10.1016/j.ejso.2009.01.011

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  54 in total

1.  One-year mortality in patients with bone and soft tissue sarcomas as an indicator of delay in presentation.

Authors:  R Nandra; N Hwang; G S Matharu; K Reddy; R Grimer
Journal:  Ann R Coll Surg Engl       Date:  2015-08-14       Impact factor: 1.891

2.  NRSN2 promotes osteosarcoma cell proliferation and growth through PI3K/Akt/MTOR and Wnt/β-catenin signaling.

Authors:  Ajimu Keremu; Xiayimaierdan Maimaiti; Abudusaimi Aimaiti; Maimaiaili Yushan; Yamuhanmode Alike; Yilizati Yilihamu; Aihemaitijiang Yusufu
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

3.  Value of diffusion-weighted images in differentiating mid-course responders to chemotherapy for osteosarcoma compared to the histological response: preliminary results.

Authors:  C Baunin; G Schmidt; K Baumstarck; C Bouvier; J C Gentet; A Aschero; A Ruocco; B Bourlière; G Gorincour; C Desvignes; N Colavolpe; G Bollini; P Auqier; P Petit
Journal:  Skeletal Radiol       Date:  2012-02-09       Impact factor: 2.199

4.  Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials.

Authors:  J S Whelan; R C Jinks; A McTiernan; M R Sydes; J M Hook; L Trani; B Uscinska; V Bramwell; I J Lewis; M A Nooij; M van Glabbeke; R J Grimer; P C W Hogendoorn; A H M Taminiau; H Gelderblom
Journal:  Ann Oncol       Date:  2011-10-19       Impact factor: 32.976

Review 5.  Has the Scottish Managed Clinical Network for Sarcoma influenced the survival outcomes for primary malignant bone tumours?

Authors:  F MacDonald; S Gupta
Journal:  J Orthop       Date:  2019-03-07

6.  Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients.

Authors:  Roelof Koster; Orestis A Panagiotou; William A Wheeler; Eric Karlins; Julie M Gastier-Foster; Silvia Regina Caminada de Toledo; Antonio S Petrilli; Adrienne M Flanagan; Roberto Tirabosco; Irene L Andrulis; Jay S Wunder; Nalan Gokgoz; Ana Patiño-Garcia; Fernando Lecanda; Massimo Serra; Claudia Hattinger; Piero Picci; Katia Scotlandi; David M Thomas; Mandy L Ballinger; Richard Gorlick; Donald A Barkauskas; Logan G Spector; Margaret Tucker; D Hicks Belynda; Meredith Yeager; Robert N Hoover; Sholom Wacholder; Stephen J Chanock; Sharon A Savage; Lisa Mirabello
Journal:  Int J Cancer       Date:  2017-12-23       Impact factor: 7.396

7.  Hyperuricemia has an adverse impact on the prognosis of patients with osteosarcoma.

Authors:  Shangzeng Wang; Xiaoya Liu; Zike He; Xinfeng Chen; Wei Li
Journal:  Tumour Biol       Date:  2015-08-18

8.  Antiproliferative effect of Tualang honey on oral squamous cell carcinoma and osteosarcoma cell lines.

Authors:  Abdulmlik A Ghashm; Nor H Othman; Mohammed N Khattak; Noorliza M Ismail; Rajan Saini
Journal:  BMC Complement Altern Med       Date:  2010-09-14       Impact factor: 3.659

9.  Telangiectatic osteosarcoma: a review of 87 cases.

Authors:  Andrea Angelini; Andreas F Mavrogenis; Giulia Trovarelli; Stefano Ferrari; Piero Picci; Pietro Ruggieri
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-28       Impact factor: 4.553

10.  Secondary osteosarcoma arising after treatment for childhood hematologic malignancies.

Authors:  Atsushi Okada; Masahito Hatori; Masami Hosaka; Munenori Watanuki; Eiji Itoi
Journal:  Ups J Med Sci       Date:  2009       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.